The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. by Fox, J. C. et al.
British JoumalofCancer(1998) 77(8), 1267-1274
© 1998 Cancer Research Campaign
The detection of K-ras mutations in colorectal cancer
using the amplification-refractory mutation system
JC Fox1, J England2, P White', G Ellison1, K Callaghan', NR Charlesworthl, J Hehir1, TL McCarthy', J Smith-Ravin2,
IC Talbot2, D Snary3, JMA Northover2, CR Newton1 and S Little1
'Zeneca Diagnostics, Gadbrook Park, Northwich, Cheshire CW9 7RA, UK; 2lmperial Cancer Research Fund, Colorectal Unit, St Mark's Hospital,
Northwick Park, Harrow, Middlesex HAl 3UJ, UK; 31mperial Cancer Research Fund, Applied Development Laboratory, Dominion House, 59 Bartholomew Close,
St Bartholomew's Hospital, London EClA 7BE, UK
Summary A total of 301 colorectal carcinoma (CRC) archival samples were analysed using the amplification-refractory mutation system
(ARMS). Each sample was examined to determine the mutation status of codons 12 and 13 of the K-ras oncogene. The results from direct
DNA sequence analysis carried out on 30 of the samples differed from the ARMS result in almost 50% of the cases as a result of the relative
excess of wild-type to mutated DNA sequences. To assess the validity of the ARMS data, the polymerase chain reaction (PCR) was used to
generate an amplicon from K-ras exon from 23 of the samples. The PCR amplicons were cloned and sequenced, and the DNA sequence
analysis of the cloned material was in agreement with the ARMS results in all but one case. This case represented a tumour that exhibited a
five-nucleotide reversed inversion. The cloned sequence data confirm the sensitivity and specificity of the individual ARMS reactions and that
it is possible in certain cases to detect additional, more complex, sequence variations.
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Colorectal cancer is the second most common malignancy in the
USA (Ries et al, 1994) and is a significant cause ofmorbidity and
mortality world-wide. The American Cancer Society estimated
that in 1995 more than 130 000 new cases ofCRC would be diag-
nosed in the USA and that there would be 54 900 deaths from the
disease (American Cancer Society, 1995). CRC onset and its
progression has been studied extensively at the molecular (Bos et
al, 1987; Forrester et al, 1987; Vogelstein et al, 1988; Burmer and
Loeb, 1989; Delattre et al, 1989; Kern et al, 1989; Vogelstein et al,
1989; Fearon and Vogelstein, 1990; El-Deiry et al, 1991; Oudejans
et al, 1991; Houlston et al, 1992; Laurent-Puig et al, 1992;
Offerhaus et al, 1992; Sharrard et al, 1992; Bell et al, 1993;
Finkelstein et al, 1993a and b; McLellan et al, 1993; Peltomaki et
al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Dix et al, 1994;
Moerkerk et al, 1994; Morrin et al, 1994; Tanaka et al, 1994;
Giaretti et al, 1995; Laird et al, 1995; Lewis et al, 1996; Span et al,
1996) and genetic (Woolf et al, 1958; Macklin et al, 1960;
Houlston et al, 1992; Zhao and Le Marchand, 1992; Peltomaki et
al, 1993; Goldgar et al, 1994; Lewis et al, 1996) levels and there is
a commonly accepted model relating tumour grade according to
Dukes' stage (Dukes, 1932) to specific DNA changes (Fearon and
Vogelstein, 1990).
It has recently been concluded that reliable CRC screening
procedures require development and that additional research is
needed to identify mutated genes in blood and stool (Young and
Levin, 1996). Although there are many examples of nucleic acid
changes having potential as tumour markers (Bos et al, 1987;
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Forrester et al, 1987; Vogelstein et al, 1988; Burmer and Loeb,
1989; Delattre et al, 1989; Kern et al, 1989; Vogelstein et al, 1989;
Fearon and Vogelstein, 1990; Jones and Buckley, 1990; Capella et
al, 1991; El-Deiry et al, 1991; Oudejans et al, 1991; Stork et al,
1991; Laurent-Puig et al, 1992; Offerhaus et al, 1992; Sharrard et
al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan
et al, 1993; Urosevic et al, 1993; Breivik et al, 1994; Dix et al,
1994; Magewu and Jones, 1994; Moerkerk et al, 1994; Morrin et
al, 1994; Tanaka et al, 1994; Giaretti et al, 1995; Laird et al, 1995;
Span et al, 1996), their value as clinical tools in cancer diagnosis,
staging or even screening needs to be demonstrated and two
important criteria must be met. First, adequate supplies ofnucleic
acid must be extracted from the clinical material; second, robust
and accurate methods ofanalysis are required. Forreliable tumour
genotyping to be useful in disease staging, any test has to be
adequately validated and there should be demonstrable benefits
over current methods.
A significant proportion of CRCs have mutations in the K-ras
oncogene (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al,
1988; Burmer and Loeb, 1989; Delattre et al, 1989; Fearon and
Vogelstein, 1990; Capella et al, 1991; Oudejans et al, 1991;
Offerhaus et al, 1992; Bell et al, 1993; Finkelstein et al, 1993a and
b; McLellan et al, 1993; Peltomaki et al, 1993; Urosevic et al,
1993; Breivik et al, 1994; Moerkerk et al, 1994; Morrin et al,
1994; Tanaka et al, 1994; Giaretti et al, 1995; Span et al, 1996). We
report a study using 301 DNA samples extracted from a colorectal
tumour bank. In this study, mutations within codons 12 and 13 of
the K-ras oncogene were investigated using amplification-refrac-
tory mutation system (ARMS) (Newton et al, 1989). Direct DNA
sequencing (Newton et al, 1988) and sequencing ofcloned ampli-
cons were then performed to assess the ARMS test results. In
almost half of the cases, the direct sequencing result detected K-
ras wild-type sequence only, this was in contrast to the ARMS
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findings in which mutations in codons 12 and 13 were detected.
However, when K-ras exon I amplicons were cloned into
Escherichia coli, the ARMS result was consistently in accord with
the sequence of the cloned material, with the exception of one
tumour that harboured a mutation offive consecutive nucleotides,
which was detected by three ofthe ARMS primers. Our data show
that ARMS is a sensitive test for detecting under-represented
nucleic acid sequences. We also demonstrate that the technique is
ideally suited to the detection of tumour DNA markers supplying
genotype information specific to prediagnosed tumours.
MATERIALS AND METHODS
DNA extraction from tumour bank samples
DNA was extracted from 301 frozen tissue samples. Positive
selection of samples comprised the exclusion of most adenomas
and tumours from familial adenomatous polyposis patients.
Altogether, the samples comprised colorectal lesions excised
between January 1985 and January 1995, six of which were
adenomas. Ofthe remaining cancers, 31 were Dukes' stage A, 135
Dukes' B and 129 Dukes' C (Dukes, 1932). Each frozen specimen
was sectioned by cryostat, 5 jim was taken for haematoxylin and
eosin staining, three or four parallel 10-im sections were trans-
ferred to sterile tubes and stored at -70°C. Fresh blades were used
for each sample. DNA extraction comprised thawing sections on
ice and the addition of sufficient sterile lysis buffer (10 mM Tris-
HCl, pH 7.5, 20% sodium dodecyl sulphate, 50 jg ml- proteinase
K) to saturate the material. After an ovemight digestion at 37°C, a
standard phenol-chloroform purification and ethanol precipitation
was carried out (Sambrook et al, 1989). The resulting DNA was
resuspended in 200 jil of 10 mm Tris-HCl (pH 7.5). DNA samples
were then stored at -70°C before quantification and K-ras muta-
tion analysis.
K-ras mutation ARMS tests
Individual ARMS tests were developed to detect specific point
mutations in the K-ras oncogene. The 3'-terminal base of each of
seven ARMS oligonucleotide primers was complementary to one
of the common mutations of codons 12 or 13 of the K-ras onco-
gene occurring in CRCs (Breivik et al, 1994) (Figure 1). In addi-
tion to the ARMS primers, a common primer complementary to
the K-ras intron sequence was included (Figure 1). Two other
primer pairs were also present in each test to give amplification
control products. Their sequences were: 5'-TATATGTGCCATGG-
GGCCTGTGCAAGGAAG-3' and 5'-CTCCTACACCCAGCC-
ATlTFTTGGC-3', which amplify part of exon IV of the cystic
fibrosis transmembrane conductance regulator (CFTR) gene
(Riordan et al, 1989), and 5'-GGGCCTCAGTCCCAACATGGC-
TAAGAGGTG-3' and 5'-CCCACCTTCCCCTCTCTCCAGG-
CAAATGGG-3', which amplify a part of each of exon II and
intron III ofthe human ax-antitrypsin gene (Newton et al, 1988).
Normal human DNA was extracted from the blood of healthy
volunteers (Ferrie et al, 1992). K-ras mutated DNA samples were
extracted from tumour derived cell lines as shown in Table 1. The
K-ras mutation for each cell line DNA was confirmed by direct
DNA sequencing as described below for tumour-derived DNA
samples. The cell line DNAs were then used to define amplifica-
tion conditions that conferred specificity to each ARMS reaction
when the following criteria were applied. First, after the DNA
Codon Codon
12 13
A(Ser)
cpA T(Cys)
....::* C(Arg)
---GTATTA ACC---GGA GCT GGT GGC GTA GGC---GAT AAA GGT---
C(Ala) cpA
T(Val)
A(Asp)
A(Asp)
Figure 1 The K-ras genomic DNA sequence; wild-type codons 12 and 13
are shown in bold type and underlined. Filled arrows (-* and *-) identify the
3' end of the ARMS primers designed to amplify individual K-ras-mutated
sequences. Open arrows (=> and 4=) identify the 3' ends of the flanking
intron. The ARMS primers were designed to detect K-rascodon 12 glycine
(GGT) to arginine (CGT), cysteine (TGT), serine (AGT), valine (GTT),
aspartic acid (GAT) and alanine (GCT) changes and the codon 13 glycine
(GGC) to aspartic acid (GAC) point mutation (23). The direction of the arrow
heads represent sense (-4 and >) and antisense (*- and =) primers. ARMS
reaction products derived from the intron-specific primercpA (X) and any of
the antisense ARMS prmers (*-) are 158 bp (codon 12 mutations) or 161 bp
(codon 13 mutation). ARMS amplicons derved from the intron-specific primer
cpB (#) and any of the sense ARMS primers (-4) are 190 bp
Table 1 Cell lines used in the development and validation of k-rasARMS
test
Mutation Cell line Source
12Ser A549 ATCC ref CRL-7909
12Cys MIA PaCa-2 ATCC ref CRL-1420
12Arg PSN-1 Yamada etal, 1986
12Ala SW1116 ATCC ref CCL-233
12Val Capan 2 ATCC ref HTB-80
12Asp Panc 1 ATCC ref CRL-1469
13Asp HCT116 ATCC ref CCL-247
amplification reaction and agarose gel electrophoresis in the pres-
ence of0.5 jg ml ethidium bromide (Sambrook et al, 1989), the
test should give a visible ARMS band only when either 102
genome equivalents of the appropriate mutant DNA with 105
equivalents of normal DNA are combined or when 102 genome
equivalents ofmutant DNA alone is tested. (A genome equivalent
meaning here the amount of genomic DNA per cell.) In addition,
there should be no visible ARMS product from any primer when
105 genome equivalents ofnormal DNA is tested in isolation. The
annealing temperature and number ofcycles used for each ARMS
reaction is shown in Table 2. All amplification reactions were
performed applying the commonly accepted precautions for
avoiding carry-over contamination (Kwok and Higuchi, 1989).
The amount of DNA extracted from each tumour sample was
measured by fluorescence after intercalation ofthe Hoechst 33258
dye (Riley et al, 1989). ARMS reactions containing these DNAs
(1 jIl each) were performed in 50jil of buffer comprising 10 mM
Tris-HCl, pH 8.3, 1.2 mm magnesium chloride, 50 mM potassium
chloride, 0.01% gelatin and dNTPs (100 mm each). The reactions
also contained mutation-specific and the appropriate intron-
specific primers (1 jM each) as shown in Figure 1. The CFTR
gene amplimers were 0.075 jM each and the aF-antitrypsin
primers were 0.025 jM each. Hot-startPCR (D' Aquilaetal, 1991;
Chou et al, 1992) was performed throughout by adding a layer of
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white mineral oil and heating the samples at 94°C for 5 min before
adding Taq DNA polymerase (1 unit). Thermal cycling comprised
35 or 36 cycles (Table 2) of 94°C, 1 min denaturation; 58-630C,
1 min annealing (Table 2); 72°C, 1 min extension. This was
followed by a final incubation at 72°C for 10 min. Any samples
that failed to amplify, identified by the absence of control bands,
were re-tested until data acquisition for all tumour samples with all
seven tests was complete.
K-ras ARMS test validation: direct sequencing of
tumour derived DNA
Tumour derived DNA (2 p1) was amplified in 50g1 reactions that
comprised 10 mm Tris-HCl, pH 8.3, 100 mm tetramethylammo-
nium chloride, 3 mm magnesium chloride, 0.05% Tween-20,
0.05% Nonidet NP40, dNTPs (200gM each) and 2.5 units of Taq
DNApolymerase. Each reaction also contained the forward primer
5'-CTGGATCTAGACTCATGAAAATGGTCAGAGAA-
ACCTTfATC-3' and the reverse primer 5'-CCTCGGAATTCG-
TACTGGTGGAGTATTTGATAGTGTATTAACC-3' (500 nM
each), which generate an amplicon from exon I ofthe K-ras onco-
gene with flankingXbaI and EcoRI restriction enzyme recognition
sites. Reactions were overlaid with mineral oil (50 p1) and
amplified over 35 cycles of94'C, 60°C, 72°C (1 min each). After
electrophoresis through a 2% metaphor agarose gel (FMC
Bioproducts), the exon I bands were excised and purified using a
Wizard DNA purification kit (Promega). Typical yields were 1-
5 gg in 50,l. The purified products were sequenced by direct
incorporation of [a35-S]dATP (Amersham) using a modified
version (Green et al, 1989) ofthe Sequenase 2.0 DNA sequencing
kit (Amersham). Annealing mixtures also contained template
DNA (6 pl), sequencing primer (1 pl, 500 ng) and dimethyl
sulphoxide (1 pl), (Sigma). Each labelling reaction was supple-
mented with 0.2 u of DNA polymerase I, Klenow fragment
(labelling grade, Boehringer Mannheim; Redston et al, 1994).
Sequencing reactions were run on 6% polyacrylamide gels that
were subsequently dried and autoradiographed.
K-ras ARMS test validation: cloning and sequencing of
tumour DNAs
An aliquot ofeach amplicon prepared for direct DNA sequencing
was also ligated into the vector pGEM-T (Promega) at 17°C
overnight. A 2 pl aliquot from each ligation mixture was used to
transform competent Escherichia coli JM109 cells (Promega).
These were plated and blue/white screened according to the
supplier's instructions. White colonies were picked into 10 ml of
sterile distilled water. PCR using the conditions described above,
but for 25 cycles, was carried out to test simultaneously for the
presence of an insert and the K-ras mutation status of any insert.
The amplimers in each reaction were the M13 5'-GTTTTCCCA-
GTCACGAC-3' (forward), 5'-CAGGAAACAGCTATGAC-3'
(reverse) primers and the ARMS primer that initially identified the
mutation. Amplification products were then visualized on a 3%
agarose gel. Clones with inserts detected by the PCR screen were
picked into 1 ml of LB broth and grown overnight at 37°C. An
aliquot (100 pl) from each was inoculated into a further 1 ml of
broth and grown for 3-4 h at 37°C. Ten p.f.u. per cell ofM13KO7
helper phage was then added to each culture. After 1 h at room
temperature, LB broth (9 ml) containing 70 mg ml-kanamycin and
100 mg ml- ampicillin was added and the culture incubated
Table 2 Annealing temperature and PCR cycle number for each K-ras
mutation-specific ARMS primer
Mutation Annealing Cycles
temperature (OC)
12Ser 60 36
12Cys 60 35
12Arg 61 35
12AIa 58 35
12Val 60 35
12Asp 63 35
13Asp 63 35
A B
1 2 3 4 5 6
C D
1 2 3 4 5 6 1 2 3 4 5 6
Figure 2 Development of the K12 Asp (A), K12 Cys (B), K13 Asp (C) and
K12 Val (D) ARMS tests. In each case, lanes 1 and 2 are tests on tumour
DNA; lane 3, 103 genome equivalents wild-type DNA; lane 4, 103 genome
equivalents mutant (cell line) DNA; lane 5, 103 genome equivalents wild-type
DNA plus 102 genome equivalents mutant DNA; lane 6, no DNA
overnight at 37°C. Virus particles were isolated by polyethylene
glycol 6000/sodium chloride precipitation, and single-stranded
DNA was isolated by phenol-chloroform extraction followed by
ethanol precipitation (Sambrook et al, 1989). DNA sequencing
was performed using the M13 forward primer as described above.
RESULTS
Histological analyses
Histological examination of the haematoxylin and eosin-stained
material confirmed the presence oftumour cells in at least 90% of
the sample in each case (data not shown).
ARMS test development
Thermal cycling and primer annealing conditions were determined
empirically, having imposed the specificity criteria described
above; these are shown in Table 2. An example showing the speci-
ficity ofeach offour ofthe tests is shown in Figure 2.
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Figure 3 Example of a typical ARMS analysis on tumour DNA. DNA from
selected Dukes' C tumours were tested using the Kl2 Ala ARMS test. Lane
1, 0x 174/Haelll size markers; lanes 2-14, tumours 1305, 5, 6, 13, 20, 21,
23, 39, 121, 122, 135, 137 and 142 respectively; lane 15, 105 genome
equivalents SW116 cell line DNA; lane 16, no DNA
Table 3 The ARMS test, direct sequencing and clone analysis results
grouped according to the ARMS primer(s) found to generate K-ras amplicons
Tumour ARMS result Dukes' stage Direct DNA sequence result
980 K12 Ser C Kl2 Ser
982 K12 Ser B K12 Ser
1271 Kl2 Ser C Kl2 Ser
23 Kl2Cys C wt
214 Kl2Cys B wt
1253 Kl2 Cys C wt
1257 K12 Cys A K12 Cys
6 Kl2 Arg C Kl2 Arg
188 K12 Val A wt
406 K12Val B K12Val
436 K12 Val B wt
561 K12 Val C K12 Val
777 K12 Val B wt
1182 K12 Val B K12 Val
1210 K12 Val A wt
1261 K12 Val C K12 Val
1289 K12 Val B wt
202 K12 Asp B wt
328 K12 Asp B K12 Asp
357 K12 Asp B K12 Asp
565 K12 Asp B wt
598 Kl2 Asp B Kl2 Asp
734 K12 Asp C Kl2 Asp
1076 K12 Asp C Kl2 Asp
72 Kl3Asp C Kl3Asp
178 Kl3Asp C Kl3Asp
302 Kl3 Asp C wt
596 Kl3 Asp C wt
863 Kl3 Asp B K13 Asp
1342 Kl2 Ser+ Arg+Ala B Multiple
DNA yield from tumour extracts
The maximum and minimum DNA yield was 124.5 jg
(622.5 ng jill) and 1.5 jig (7.5 ng il-'), respectively, approximating
to between 1.25x105 and 1.5x103 human diploid genome equiva-
lents jil'. Six ofthe Dukes' C samples failed to give sufficient DNA
to reach the threshold ofdetection, but this did not preclude ARMS
analyses of these samples. In general, a lower yield of DNA was
Figure 4 Three-primer PCR with cloned K-ras exon amplicons. Lanes 1
and 48, 0x 174/Hae IlIl size markers; lanes 2-46, PCR aliquots from
reactions carried out with the Ml 3 forward and reverse primers and the
ARMS primer that gave the preliminary ARMS result. High-molecular-weight
bands represent presence of cloned insert; low-molecular-weight bands
represent no insert present in clone; intermediate-molecular-weight bands
are derived from the respective ARMS primer and one or other of the Ml3
primers, the slightly different sizes of these result from whether a sense or
antisense ARMS primer was used. Lane 47, no DNA
associated with the extracts from Dukes' C classified tumours. The
mean DNA yield was 25.6jg (128.0 ng il-'), approximately
2.5x104 genome equivalents tl-1, after discounting the six samples
that failed to give measurable quantities ofDNA extract.
ARMS tests and direct sequencing
A typical ARMS result is shown in Figure 3. A summary of the
K-ras mutations detected using ARMS, the Dukes' stage of the
tumour and the direct DNA sequencing result for 30 ofthe tumour
DNAs examined is shown in Table 3.
Quantitative analysis of K-ras mutations
Three primer PCR results used to classify clones from a selection
of tumour DNAs are shown in Figure 4. Table 4 provides an
analysis of the ARMS data, direct DNA sequencing and clone
analyses from equivalent samples.
K-ras mutational analysis of the 301 tumour bank
samples
As the majority ofCRCs were classified as eitherDukes' B or C at
the time ofsurgery, a relatively smaller number ofDukes' A (31 in
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Table 4 Direct and cloned sequence results from tumour DNAs grouped according to the ARMS primer that initially characterized the K-ras
mutation harboured by the tumour
Tumour DNA ARMS result Direct sequence Frequency of Sequence of ARMS-
result mutation in clones positive clones
1271 12 Ser 12 Ser 5 of 27 (19)a 12 Ser
1342 12 Ser Unclear 16 of 28 (57) Five mutations
23 12 Cys wt 14 of 38 (37) 12 Cys
214 12 Cys wt 12 of 33 (36) 12 Cys
500 12 Cys wt 10 of 33 (30) 12 Cys
530 12 Cys wt 2 of 34 (6) 12 Cys
1253 12 Cys wt 21 of 43 (49) 12 Cys
6 12 Arg 12 Arg 4 of 10 (40) 12 Arg
957 wt wt 0 No positive clones
1342 12Arg Unclear 0 No positive clones
1342 12 Ala Unclear Not done Not done
188 12 Val wt 8 of 39 (21) 12 Val
436 12Val wt 11 of 33 (33) 12 Val
556 12 Val 12 Val 12 of 37 (32) 12 Val
777 12 Val 12 Val 4 of 38 (10) 12 Val
1210 12 Val wt 3 of 42 (7) 12 Val
1289 12 Val 12 Val 10 of 38 (26) 12 Val
177 12Asp wt 15of41 (37) 12Asp
202 12 Asp wt 2 of 12 (21) 12 Asp
357 12 Asp 12 Asp 20 of 41 (49) 12 Asp
410 12 Asp wt 7of 37 (19) 12 Asp
546 12 Asp wt 3of 39 (8) 12 Asp
565 12Asp wt 2 of 34 (6) 12Asp
302 13 Asp wt 4of41 (10) 13 Asp
596 13Asp wt 5of24(21) 13Asp
aNumbers in parentheses are percentages.
Table 5 Analysis of the frequencies of the K-ras mutations detected using ARMS from all samples from the CRC tumour bank
Tumour Frequencies Frequencies Frequencies
(male patients) (female patients) (all patients)
K-raspositive K-rasnegative K-raspositive K-ras negative K-raspositive K-rasnegative
Adenoma 1 of4 (25)a 3of4 (75) 0of2 (0) 2of 2 (100) 1 of6 (17) 5of 6 (83)
Dukes'A 5of 15(33) 10of 15 (67) 8 of 16 (50) 8of 16(50) 13of 31 (42) 18of 31 (58)
Dukes' B 24 of 74 (32) 50 of 74 (68) 23 of 61(38) 38 of 61 (62) 47 of 135 (35) 88 of 135 (65)
Dukes'C 28of90 (31) 62of 90 (69) 20of 39 (51) 19of39 (49) 48of 129 (37) 81 of 129 (63)
aNumbers in parentheses are percentages.
total, 10.3%) cancers were analysed. There were six adenomas in
total (2%) for the same reason and also because of the deliberate
selection against these. In the 295 tumours, there were more from
male than femalepatients (183 male, 118 female); 36% had K-ras
mutations and there were relatively higher numbers of severe
diseasepatients: 31, 135 and 129 Dukes' stagesA, B and C respec-
tively. There wererelatively more severe male than femalepatients
(male-female ratio for each Dukes' stage is A, 15:16; B, 74:61; C,
90:39; P <0.05). For theproportion ofK-ras mutations, there was
evidence that this was less (P < 0.05) for men (31.7%) than for
women (43.2%). There was no evidence that the proportions
differed across Dukes' stages either for the sexes separately or
combined (combined proportions, Dukes' A, 13:18, 42%; Dukes'
B, 47:88, 35%; and Dukes' C 48:81, 37%; P > 0.05). Table 5
shows the results based on which the K-ras codons 12 and 13
mutational analysis was made and the relative K-ras mutation
frequencies.
DISCUSSION
Many studies have examined the association of K-ras mutations
with CRC (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al,
1988; Bos, 1989; Burmer and Loeb, 1989; Vogelstein et al, 1989;
Capella et al, 1991; Oudejans et al, 1991; Sidransky et al, 1992;
Bell et al, 1993; Finkelstein et al, 1993a and b; McLellan et al,
1993; Urosevic et al, 1993; Breivik et al, 1994; Moerkerk et al,
1994; Morrin et al, 1994; Giaretti et al, 1995; Hasegawa et al,
1995; Hayashi et al, 1995; Ranaldi et al, 1995; Carpenter et al,
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1996; Span et al, 1996; Villa et al, 1996). However, there are
significant differences in reported frequencies of K-ras mutations
in CRC (McLellan et al, 1993). Inconsistencies between studies
could be due to one or more of several factors. These include the
number oftumours investigated, the methods used and the number
of individual point mutations tested for. It is therefore difficult to
state the true number ofCRCs that contain K-ras mutations.
The aims of our study were to develop validated tests for seven
K-ras point mutations and to apply them in a thorough investiga-
tion of the incidence of the mutations in tumours from a large
cohort of CRC patients. As part of the ARMS test validation
process we used the sequencing strategy described in Materials
and methods. Our initial approach to directly sequence PCR
amplicons verified the ARMS result inapproximately half of the
tumour DNA samples investigated. One possible explanation for
this could be that the ARMS tests failed to discriminate mutated
from normal sequences. The tumours were not microdissected.
However, a large proportion of tumour cells relative to normal
tissue was identified by histology. Assuming that the tumour cells
were monoclonal for any given K-ras mutation, the ratio of mutant
to normal DNA might then be expected to be relatively high. K-
ras is an oncogene, thus there is no reason to suppose that the
normal copy of the gene should not be present in K-ras mutant
tumour cells, unlike in the occurrence of allele loss with tumour-
suppressor genes (Kem et al, 1989; Vogelstein et al, 1989; Fearon
and Vogelstein, 1990). Therefore, when taking into account the
presence of normal DNA, the mutant sequences could actually be
expected to account for only a small proportion of the total DNA
of the sample and so go undetected by direct DNA sequencing.
This is upheld by our observations, and we therefore concluded
that direct DNA sequencing was inappropriate for substantiating
the ARMS results. This was confirmed by the second stage ofvali-
dation in which cloned amplicons of K-ras exon I were sequenced.
Here, the DNA sequence data gave similar results to those derived
by ARMS. The results from this stage ofvalidation therefore indi-
cate the use of a method that will detect mutations that are under-
represented against a background of wild-type alleles. The ARMS
tests described herein were validated to a sensitivity of at least one
mutant ras sequence in 103 wild-type sequences. In fact, control
reactions for tumour DNA analysis had routinely lower ratios of
mutant to wild-type input DNA. Other groups (Ehlen and Dubeau,
1989; Stork et al, 1991; Cha et al, 1992; Hasegawa et al, 1995;
Hayashi et al, 1995; Carpenter et al, 1996) have reported tests
based on the same principles as the ARMS tests described here.
Detection levels of mutant ras sequences present at as low as 1 in
105 wild-type sequences have been reported (Ehlen and Dubeau,
1989; Cha et al, 1992) and 1 in 103 (this study and Carpenter et al,
1996). This ability of the technique to detect rare mutations in a
background of normal DNA demonstrates its potential role in
screening or in the monitoring ofresidual disease.
ARMS is a simple and accurate method and has several benefits
over other PCR-based mutation detection systems. Specifically,
the technique does not require the use of radioisotopes or the
multiple probing of immobilized PCR amplicons (McLellan et al,
1993; Breivik et al, 1994; Villa et al, 1996) or cloned PCR ampli-
cons (Sidransky et al, 1992). The technique avoids the DNA
sequencing ofsingle-strand conformation polymorphism products
(Span et al, 1996), a technique that could be expected to be
constrained by sequence under-representation as discussed above.
Similarly, under-represented mutant sequences could go unde-
tected using PCR in conjunction with restriction fragment length
polymorphism (Chen and Viola, 1991), which is limited to low
cycle numbers for the PCR to avoid false-positive results. ARMS
can be performed such that carry-over contamination is avoided
(Kwok and Higuchi, 1989), as it was in the studypresented herein.
There is a severe limitation of the studies that have examined the
elimination ofthe BstNI restriction site at codon 12 in some K-ras
mutations (Levi etal, 1991; Carpenter etal, 1996). This is because
these tests rely on a BstNI restrictiondigest part waythrough PCR
cycling. Previously generatedamplicons therefore have the poten-
tial to cause carry-over contamination when PCR is resumed. In
effect, it is not possible to keep PCR set-up and PCR analysis
separated, a major drawback in the clinical setting.
One DNA sample analysed gave a positive result in more than
one ARMS test. Sample 1342 was derived from a Dukes' B rectal
tumour from a49-year-old man. This sample gave apositive result
with the K12 glycine (GGT) to arginine (CGT), serine (AGT) and
alanine (GCT) tests. Direct sequenceanalysis was non-informative
but DNA sequencing of each of the cloned PCR amplicons
revealed a five-nucleotide mutation. The normal sequence for
codons 11-13 (GCT GGT GGC) was changed to GCC ACC AGC
such that there is a reversed inversion of the last nucleotide of
codon 11 to the first nucleotide of codon 13, resulting in a K12
glycine to threonine and K13 glycine to serine mutantprotein. Such
an occurrence could possibly be the result of an aberrant recom-
binogenic event. The DNA sequencing results therefore exclude
the possibility that tumour 1342 is polyclonal for more than one K-
ras point mutation. None of the tumours analysed were found to
have more than one K-ras mutation, also the overall frequency of
K-ras mutation did not increase significantly between Dukes'
stages. This supports the model that K-ras mutation is arelatively
early event in the progression of CRC through Dukes' stages A to
C (Fearon andVogelstein, 1990). Becauseonly six adenomas were
included in this study, the exact timing of K-ras mutation in the
adenoma to carcinomaprogression was not addressed.
The value of K-ras mutations as a marker of malignancy will
depend on severalfactors, not leastbeing thefrequency oftumours
of a given tumour type, such as CRC, that carry the mutation. As
this study has found the frequency of K-ras mutation to be
approaching 40%, additional markers for CRC would be required
for general screening purposes if all CRCs were to be identified
using ARMS. Tumour genotyping tests can be used for disease
staging (Hayashi et al, 1995). However, the value of tumour
genotyping for screening for CRC by the identification of DNA
changes is unknown. Studies have begun to address the clinical
significance ofDNAtesting (Oudejans et al, 1991; Sidransky etal,
1992; Bell et al, 1993; Finkelstein et al, 1993a; Hasegawa et al,
1995; Hayashi et al, 1995; Petersen, 1995; Ranaldi et al, 1995;
Span et al, 1996; Villa et al, 1996). The ARMS tests described
herein have been applied for clinical purposes. The significance
and the findings ofthese studies will bepublished separately.
ABBREVIATIONS
ARMS, amplification-refractory mutation system; CFIR, cystic
fibrosis transmembrane conductance regulator; CRC, colorectal
cancer; PCR,polymerase chainreaction;p.f.u.,plaque-forming units
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